503B outsourcing facilities and semaglutide: registration, inspection and GLP-1 records
Which 503B outsourcing facilities make semaglutide?
FDA does not publish which drugs each registered outsourcing facility makes, and on April 1, 2026 it stated that semaglutide is on neither the 503B bulks list nor its drug shortage list, the two routes for outsourcing facilities to compound from bulk semaglutide. 6 facilities on FDA’s list of 100 (updated Nov 6, 2026) also appear in FDA warning letters or recall reports naming GLP-1 drugs in this index.
A record here is not a recommendation or a rating. This site does not rank facilities.
| Apollo Care | Columbia, MO | Jul 28, 2026 | Yes | 0 | 11 |
| Apothecary Pharma, LLC | Cary, NC | Sep 2, 2026 | Yes | 1 | 1 |
| GenoGenix LLC | Raton, FL | Jul 18, 2025 | Yes | 1 | 4 |
| PQ Pharmacy LLC | Brooksville, FL | Jun 1, 2026 | Yes | 1 | 0 |
| ProRx LLC | Exton, PA | Sep 19, 2025 | Yes | 2 | 14 |
| Tailstorm Health Inc. | Chandler, AZ | Aug 28, 2026 | Yes | 1 | 0 |
The full list of 100 facilities, each with its own page of registration dates and FDA inspections, is on the 503B facilities page.
FDA’s 503B list does not name products, but outsourcing facilities that assign NDCs report their compounded products to FDA’s NDC Directory: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?
FDA’s statements on outsourcing facilities and semaglutide
- Feb 21, 2025: FDA determined that the shortage of semaglutide injection products is resolved. FDA said it did not intend to take action, for violations that depend on semaglutide being on the shortage list, against 503A pharmacies and physicians until April 22, 2025, or 503B outsourcing facilities until May 22, 2025 (or a pending court decision, whichever was later). The same update listed liraglutide injection as in shortage. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 24, 2025: A federal district court denied the preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). FDA stated (update dated April 28, 2025) that the enforcement discretion period for 503A semaglutide compounding had ended, and that for 503B outsourcing facilities it ran until May 22, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Jun 26, 2026: FDA extended to July 30, 2026 the comment period on its proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. Source: Federal Register, June 26, 2026: Extension of Comment Period
Common questions
Can a public record say which 503B outsourcing facility to use for semaglutide?
No. A record cannot rank facilities, and this site does not. What the records show is each facility’s FDA registration dates, last inspection, Form 483 status and dated FDA actions, on each facility’s page.
What is a 503B outsourcing facility?
A compounder registered with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. Outsourcing facilities are subject to FDA inspection and current good manufacturing practice requirements, and FDA lists each one with its last inspection date.
What is a Form FDA 483?
A form FDA investigators issue at the end of an inspection listing conditions they observed that may violate the law. It is not a final agency determination.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Records last pulled Nov 15, 2026. Every entry links to the original public record.